Development of inactivated poliovirus vaccine derived from Sabin strains

Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine

“…Therefore, the number of D-antigen units (DU) of each type of sIPV is needed to adjust the content of antigen in the vaccine so that it will induce neutralizing antibody titers equal to those of cIPVs. It was then confirmed that 3 DU, 100 DU, and 100 DU of types 1, 2 and 3 sIPVs, respectively, had the same immunogenicity in rats as cIPVs [11].…”

“…Therefore, Shimizu et al tried to find the amounts of sIPVs that possess the same immunogenicity as cIPVs (40 DU, 8 DU, and 32 DU for types 1, 2, and 3, respectively) and estimated the amounts of sIPV as 3 DU, 100 DU, and 100 DU for types 1, 2, and 3, respectively, in rats [11]. Based on this information, we tried to determine the optimal dose of sIPV in a DTaP-sIPV.…”

Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan

“…JPRI was the only OPV-producing manufacturer in Japan [JPRI merged with the Research Foundation for Microbial Diseases of Osaka University (Biken) in April 2014] [37][38][39][40][41] (Fig. 1).…”

“…JPRI had established a sIPV production system based on Vero cell microcarrier cultures and implemented quality assurance and control systems to measure the antigen content and immunogenicity of the formalin-inactivated sIPV antigen for each serotype [37][38][39]43]. Using Vero cells in a tight monolayer on microbeads in the microcarrier cultures, JPRI had established a high-yield production system of poliovirus materials [37,38].…”

“…1). Considering biosafety and containment perspectives [4,5,42], JPRI attempted to develop IPV derived from attenuated Sabin strains (sIPV), instead of using virulent poliovirus strains, that have been used for the conventional Salk IPV (cIPV) products since the beginning of sIPV development [37][38][39][40][41].…”